- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- Pegylated recombinant factor VIII
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
Pegylated recombinant factor VIII
| EU orphan designation number: | EU/3/12/995
|
| Active ingredient: | Pegylated recombinant factor VIII |
| Indication: | Treatment of haemophilia A |
| Sponsor: | Novo Nordisk A/S
Novo Allé, DK-2880 Bagsvaerd, Danmark |
Public summary of scientific opinion
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 30/04/2012 | Orphan designation | EMA/OD/144/11 | (2012)2990 of 26/04/2012 |
CONTACT
EU links
Directorate General Health & Consumers